53 recruiting. 53 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Recruiting 53 |
| Phase 2 | 15 | Recruiting 15 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-11-01 | 2026-10-27 |
| Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma CHF10136, CHF10136 matched placebo - Asthma, Healthy Volunteers | Phase 1 | Recruiting | Chiesi Farmaceutici S.p.A. | 120 | 2026-10-02 | 2026-10-13 |
| Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis QX4533, QX4533 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | QuantX Biosciences, Inc. | 84 | 2026-09-14 | 2026-10-02 |
| A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma SKB575, Placebo - Asthma (Diagnosis) | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 36 | 2026-08-25 | 2026-09-10 |
| A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis BYN-001, Placebo - Atopic Dermatitis, Healthy Participants | Phase 1 | Recruiting | Bionyra Pharma | 56 | 2026-08-17 | 2026-09-30 |
| A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers AMG 691 - Healthy Participants | Phase 1 | Recruiting | Amgen | 28 | 2026-08-07 | 2026-08-27 |
| A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 GSK5784283 - Asthma | Phase 1 | Recruiting | GlaxoSmithKline | 24 | 2026-07-17 | 2026-07-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| Single Ascending and Multiple Ascending Dose Study of LCA-0061 LCA-0061, Placebo - Atopic Disease, Peanut Allergies | Phase 1 | Recruiting | Lycia Therapeutics, Inc. | 72 | 2026-06-26 | 2026-07-14 |
| Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis ITI-9001, Placebo - Allergen Immunotherapy | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 45 | 2026-06-20 | 2026-09-25 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma PF-08103402, Placebo, Midazolam - Healthy Volunteer Study, Healthy Adults | Phase 1 | Recruiting | Pfizer | 133 | 2026-06-17 | 2026-10-13 |
| A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis DCY636, Placebo - Dermatitis, Atopic | Phase 1 | Recruiting | Novartis Pharmaceuticals | 63 | 2026-06-02 | 2026-08-19 |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| A Study of CDX-622 in Participants With Mild to Moderate Asthma CDX-622 - Mild to Moderate Asthma | Phase 1 | Recruiting | Celldex Therapeutics | 12 | 2026-06-01 | 2026-07-02 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis REGN20423, Placebo - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 144 | 2026-05-22 | 2026-10-07 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults EDP-978, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 1 | Recruiting | Enanta Pharmaceuticals, Inc | 98 | 2026-04-01 | 2026-04-21 |
| A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants SKB575 Injection/SKB575 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 90 | 2026-03-31 | 2026-05-08 |
| Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 ARQ-234, Placebo - Atopic Dermatitis (AD), Eczema | Phase 1 | Recruiting | Arcutis Biotherapeutics, Inc. | 125 | 2026-03-02 | 2026-10-23 |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
Showing 20 of 53. Sign in to see all of them.
Dermatitis, Atopic (21) · Asthma (14) · Peanut Hypersensitivity (6) · Eczema (4) · Chronic Urticaria (3) · Pulmonary Disease, Chronic Obstructive (3) · Arthritis, Rheumatoid (2) · Chronic Inducible Urticaria (2) · Hypertension, Pulmonary (2) · Lung Diseases (2) · Lung Diseases, Interstitial (2) · Psoriasis (2) · Amyloidosis (1) · Anaphylaxis (1)
Immune System Diseases (53) · Hypersensitivity, Immediate (50) · Skin and Connective Tissue Diseases (28) · Skin Diseases (27) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (24) · Genetic Diseases, Inborn (24) · Skin Diseases, Genetic (22) · Dermatitis (21) · Skin Diseases, Eczematous (21) · Lung Diseases, Obstructive (15) · Respiratory Hypersensitivity (15) · Respiratory Tract Diseases (15) · Bronchial Diseases (14) · Lung Diseases (13)
Adenosine Triphosphate (1) · Bronchoscopy (1) · Gels (1) · Immunotherapy (1) · Midazolam (1) · Saline Solution (1) · Vancomycin (1) · baricitinib (1) · semaglutide (1)
Bambusa Therapeutics (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · GlaxoSmithKline (2) · Pfizer (2) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (2) · The First Affiliated Hospital of Soochow University (2) · Amgen (1) · Arcutis Biotherapeutics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · BeOne Medicines (1) · Benjamin Medoff (1) · Bionyra Pharma (1) · Brexogen Inc. (1) · Celldex Therapeutics (1) · Chiesi Farmaceutici S.p.A. (1)
United States (22) · China (13) · Australia (7) · New Zealand (5) · Canada (4) · United Kingdom (4) · Germany (2) · Japan (2) · Spain (2) · Switzerland (2) · Belgium (1) · France (1) · Greece (1) · Jordan (1) · Netherlands (1)
Alexandra F Freeman, M.D. (1) · Ana Tabar, PhD, MD (1) · Benjamin D Medoff, MD, PhD (1) · David Berk, MD (1) · Donald Leung, MD, PhD (1) · George H. Luciuk, MD (1) · Jennifer Martin, MD (1) · Lisa Li (1) · Mark Kowalski, MD PhD (1) · Marta Ferrer, PhD, MD (1)
2025 (3)